Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
A Photographer’s Rare Blood Cancer Symptoms Come to Life Through Generative AI
Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...
Targeted Oncology1d
Next-Generation Approaches and Future Directions in PV Care
A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) ...
Targeted Oncology1d
Advanced Therapeutic Algorithms for PV Treatment Sequencing
A panelist discusses how available therapeutic strategies have enhanced their approach to treatment sequencing in patients with polycythemia vera (PV) by providing a broader armamentarium that allows ...
Physician's Weekly4d
Shaping the Future of PV Treatment Through Molecular Understanding
Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...
Le Lézard5d
Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...
Le Lézard5d
Pint Pharma Announces ANVISA's Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia ...
The American Journal of Managed Care6d
Understanding Hematocrit Thresholds in Polycythemia Vera Treatment
Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...